Ask AI
ET Case Challenge

CME

Interactive Case Challenge: Diagnosing and Managing a Patient With Essential Thrombocythemia

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: April 06, 2026

Expiration: October 05, 2026

Activity

Progress
1 2
Course Completed

References 

  1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
  2. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
  3. Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166-179.
  4. Harrison CN, Vannucchi AM. Closing the gap: genetic landscape of MPN. Blood. 2016;127:276-278.
  5. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59:171-191.
  6. Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589-3597.
  7. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.
  8. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128-5252.
  9. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697-718.
  10. Harrison C, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
  11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myeloproliferative neoplasms. v1.2026. Accessed March 30, 2026.
  12. Mesa RA, Gill H, Xiao Z, et al. Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial. Presented at: 2025 American Society of Clinical Oncology Annual Meeting; May 28, 2025. Abstract 6500.
  13. Harrison C, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130:1889-1897.
  14. Goethert JR, Gill H, Palandri F, et al. Bomedemstat (IMG-7289), an LSD1 inhibitor, manages the signs and symptoms of essential thrombocythemia (ET) while reducing the burden of cells homozygous for driver mutations. Presented at: 2025 American Society of Hematology Annual Meeting; December, 2023. Abstract 747.
  15. Passamonti F, Patriarca A, Knapper S, et al. Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from the MANIFEST study. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 7019.